The KQ Labs portfolio

CamMed exists to deliver safer, easier, and faster medicines and therapies to patients. Our team is on a mission to leverage next-generation mRNA technology to make therapeutics and vaccines more effective, at lower doses, with fewer side effects.

Personalising cancer care with AI-powered prediction of treatment response.

Developing an AI-enabled therapeutics platform for monogenic and common diseases.

Data, AI and remote diagnostics to unlock fertility care for 200 million patients.

Kanjo’s pre-diagnostic model for mental health, brings clinical research into clinical practice and enables clinicians to reduce rates of misdiagnosis, triage resources appropriately and monitor their patients with higher degrees of accuracy.

LinkGevity is a trailblazing biotech at the intersection of AI and longevity. Utilizing a proprietary Blueprint Theory of Aging, they map key molecular pathways driving aging and deterioration. Their flagship therapeutic earned a spot in the prestigious NASA/Microsoft Space-H Program, showcasing its groundbreaking potential for health on Earth and in space.

Innovating Inhaled Medicines.

Oxford Ion Sight enables drug discovery through an innovative native mass spectrometry platform.

We are a Functional Precision Medicines Platform company, optimizing therapeutic outcomes for cancer patients.

Accurate, Accessible and Scalable ECG diagnostics.

Beautiful Voice employs AI and gamification to modernise speech and language therapy delivery, making high-quality speech and language therapy more accessible, efficient and data-driven for patients, speech and language therapists and caregivers

CC Bio combines synthetic biology principles with big data to develop precision microbiome editing technologies.

Juniver is transforming the $66bn eating disorder market through a first-of-its-kind platform shown to be 92% effective in a pilot and designed to cover the full continuum of care, from self-guided experiences proven to drive symptom reduction to a 1:1 virtual clinic.

Octiocor’s AI-driven software interprets intravascular coronary artery images for clinical trial analysis and to prevent future heart attacks in high-risk patients.

PebbleSense uses artificial intelligence (AI) and biometric data to detect and manage pressure ulcers alongside other debilitating health conditions for marginalised groups of patients.

Drugging 'undruggable' proteins with aptamer therapeutic drugs designed with AI

Plurify enables the next generation of universal cell therapies using a novel purification technology.

Siloton is a health tech company that aims to improve outcomes for patients with chronic diseases by providing highly accessible eye-scanning devices.

Increasing representation of minority groups (women, black and ethnic minorities) in pre-clinical research and clinical trials by the appropriate amount according to diseases such as breast cancer, which promotes drug characterisation and improves drug efficacy and safety in these groups.

Unison is the secure omics data infrastructure for the future of personalised medicine